ABUS

Arbutus Biopharma Corp

Feb 05 • 04:00PM ET

3.67

-0.21 -5.41 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN ALNY MRNA VRTX EXEL NBIX BMRN SRPT BLUE

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA KOMP VHT

Index	RUT	P/E	-	EPS (ttm)	-0.22	Insider Own	21.83%	Shs Outstand	191.95M	Perf Week	-11.14%
Market Cap	705.83M	Forward P/E	-	EPS next Y	-0.16	Insider Trans	0.00%	Shs Float	150.34M	Perf Month	-23.38%
Enterprise Value	616.74M	PEG	-	EPS next Q	-0.04	Inst Own	60.96%	Short Float	8.69%	Perf Quarter	-18.44%
Income	-42.28M	P/S	48.31	EPS this Y	50.59%	Inst Trans	-0.05%	Short Ratio	9.35	Perf Half Y	5.76%
Sales	14.61M	P/B	9.10	EPS next Y	14.78%	ROA	-35.50%	Short Interest	13.07M	Perf YTD	-23.70%
Book/sh	0.40	P/C	7.53	EPS next 5Y	-	ROE	-45.88%	52W High	5.10 -28.04%	Perf Year	9.23%
Cash/sh	0.49	P/FCF	-	EPS past 3/5Y	23.21% 33.46%	ROIC	-51.89%	52W Low	2.70 35.67%	Perf 3Y	21.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-17.50% 0.53%	Gross Margin	95.31%	Volatility	11.53% 6.81%	Perf 5Y	-2.91%
Dividend TTM	-	EV/Sales	42.21	EPS Y/Y TTM	47.93%	Oper. Margin	-214.67%	ATR (14)	0.30	Perf 10Y	12.92%
Dividend Ex-Date	-	Quick Ratio	18.80	Sales Y/Y TTM	116.64%	Profit Margin	-289.45%	RSI (14)	32.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	18.80	EPS Q/Q	61.27%	SMA20	-13.96%	Beta	0.73	Target Price	6.00
Payout	-	Debt/Eq	0.06	Sales Q/Q	-60.49%	SMA50	-17.61%	Rel Volume	1.15	Prev Close	3.88
Employees	44	LT Debt/Eq	0.05	Earnings	Nov 13 BMO	SMA200	-6.88%	Avg Volume	1.40M	Price	3.67
IPO	Jul 23, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-33.33% -58.24%	Trades		Volume	1,605,769	Change	-5.41%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy	$5
Feb-25-21	Initiated	Jefferies	Hold	$5
Dec-17-20	Initiated	H.C. Wainwright	Buy	$10
Jul-27-20	Resumed	JMP Securities	Mkt Outperform	$10 → $8
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$5
Feb-20-20	Initiated	Robert W. Baird	Outperform	$8
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$10
Oct-07-19	Reiterated	B. Riley FBR	Buy	$7 → $3
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy	$11.50 → $9
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral	$5
Oct-12-18	Reiterated	Chardan Capital Markets	Buy	$12 → $6.50
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral	$9 → $9
Mar-19-18	Resumed	Chardan Capital Markets	Buy	$8.25
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral	$9 → $6
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy	$3 → $6
Feb-01-17	Reiterated	Wedbush	Outperform	$13 → $10

Show Previous Ratings

Jan-12-26 12:00PM	Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-25 07:30AM	Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -5.79%
Oct-07-25 08:00AM	Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2025 (GlobeNewswire)
Oct-03-25 09:40AM	Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? (Zacks)
Sep-17-25 09:40AM	Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:40AM	Loading…
Sep-01-25 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-14-25 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-25 08:40AM	Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates (Zacks)
07:45AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-25-25 07:30AM	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus (GlobeNewswire)
May-14-25 08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:39AM	Arbutus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-13-25 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
09:40AM	Loading…
09:40AM	Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-07-25 02:01AM	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 (GlobeNewswire)
Apr-25-25 09:40AM	Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-24-25 10:02AM	Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-23-25 02:01AM	Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 (GlobeNewswire)
Mar-31-25 12:00PM	All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy (Zacks)
09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-25 09:48AM	Arbutus Biopharma: A Wing And A Prayer (Seeking Alpha) +7.03%
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
07:01AM	Novo gains Lexicon obesity drug; CRISPR COO to step down (BioPharma Dive)
Mar-27-25 08:45AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-26-25 03:45PM	As Vaccine Skepticism Mounts, Modernas Business Grows More Precarious (Barrons.com)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire)
Feb-25-25 07:00AM	Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO (GlobeNewswire)
09:24AM	Loading…
Feb-12-25 09:24AM	Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Jan-16-25 11:22AM	Jim Cramer on Arbutus Biopharma Corporation (ABUS): It Loses Money (Insider Monkey)
Jan-13-25 07:30AM	Arbutus Provides 2025 Corporate and Financial Update (GlobeNewswire)
Dec-06-24 08:20AM	Heres Why Arbutus (ABUS) Surged in Q3 (Insider Monkey)
Dec-03-24 08:00AM	Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors (Business Wire)
Nov-26-24 07:30AM	Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat (GlobeNewswire)
Nov-15-24 11:02AM	Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon (GlobeNewswire)
11:01AM	Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B (GlobeNewswire)
Nov-14-24 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 02:12AM	Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
02:07AM	Q3 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 08:45AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-23-24 07:30AM	Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-15-24 08:16AM	Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.48%
Oct-01-24 07:30AM	Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (GlobeNewswire)
Sep-25-24 09:40AM	Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-03-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-22-24 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-24 09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-02-24 01:51AM	Q2 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 08:40AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-18-24 07:30AM	Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Jun-06-24 11:15AM	Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels (GlobeNewswire) -7.99%
11:15AM	Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B (GlobeNewswire)
Jun-05-24 02:30AM	Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure (GlobeNewswire) +8.68%
May-29-24 07:30AM	Arbutus to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 02:00AM	Arbutus to Present Imdusiran Data at EASL Congress 2024 (GlobeNewswire) +6.23%
May-17-24 12:03PM	Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
10:40AM	Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
09:00AM	Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value (Business Wire)
May-07-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-03-24 11:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:24AM	Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:55PM	ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:58AM	Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:44AM	Arbutus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:25AM	Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 (GlobeNewswire)
Apr-30-24 09:40AM	Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? (Zacks)
Apr-18-24 07:30AM	Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-04-24 08:30AM	Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna (GlobeNewswire)
Mar-08-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-24 08:17AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:14PM	Q4 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
08:40AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-15-24 07:30AM	Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jan-08-24 07:30AM	Arbutus Announces 2024 Corporate Objectives and Provides Financial Update (GlobeNewswire)
Nov-09-23 04:24PM	Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD (GlobeNewswire)
04:01PM	Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting (GlobeNewswire)
09:12AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
01:16AM	Q3 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:05AM	Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:15AM	Arbutus Announces CEO, William Collier, to Retire December 31, 2023 (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-24-23 07:30AM	Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-18-23 07:30AM	Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference (GlobeNewswire) -5.82%
Oct-11-23 08:05AM	Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2023 (GlobeNewswire)
Sep-12-23 10:56AM	Arbutus BioPharma narrows research focus to extend cash runway (American City Business Journals) -7.73%
08:58AM	Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up (Zacks)
Sep-11-23 04:15PM	Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended (GlobeNewswire)

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
McElhaugh Michael J.	Director	Apr 21 '25	Proposed Sale	3.26	246,886	804,850	Apr 21 02:11 PM
McElhaugh Michael J.	Director	Apr 15 '25	Proposed Sale	3.20	53,114	170,098	Apr 15 04:27 PM
Sofia Michael J.	Officer	Mar 31 '25	Proposed Sale	3.50	250,000	875,000	Mar 31 09:42 AM
Sofia Michael J.	Officer	Mar 24 '25	Proposed Sale	3.28	250,000	820,000	Mar 24 09:19 AM
Sofia Michael J.	Officer	Mar 19 '25	Proposed Sale	3.20	150,000	480,000	Mar 19 09:34 AM
Sofia Michael J.	Officer	Mar 13 '25	Proposed Sale	3.38	100,000	338,000	Mar 13 03:55 PM
Sofia Michael J.	Member of immediate family of	Mar 07 '25	Proposed Sale	3.29	167,162	549,963	Mar 07 02:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABUS

Arbutus Biopharma Corp

Upgrade your FINVIZ experience